W. W. ten Bokkel Huinink

发表

J. Mcvie, H. Pinedo, J. Vermorken, 1991, European journal of cancer.

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.

J. Mcvie, J. Vermorken, W. van der Vijgh, 1987, British Journal of Cancer.

Phase II studies of Elsamitrucin in breast cancer, colorectal cancer, non-small cell lung cancer and ovarian cancer. EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Assessment of anthracycline-related myocardial adrenergic derangement by [123I]metaiodobenzylguanidine scintigraphy.

H. van Tinteren, P. Bruning, R. V. Valdés Olmos, 1995, European journal of cancer.

Multivariate analysis of prognostic factors in patients with disseminated nonseminomatous testicular cancer: results from a European Organization for Research on Treatment of Cancer Multiinstitutional Phase III Study.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1987, Cancer research.

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.

L. Collette, R. Sylvester, R. de Wit, 1998, British Journal of Cancer.

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study

J. Schellens, J. Beijnen, D. Pluim, 2002, Anti-cancer drugs.

Clinical evidence for topotecan-paclitaxel non--cross-resistance in ovarian cancer.

M. Gore, J. Carmichael, N. Davidson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Telephone-based nursing intervention improves the effectiveness of the informed consent process in cancer clinical trials.

N. Aaronson, M. Muller, C. Koning, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

D. Rea, D. Richel, C. Punt, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU).

E. Van Cutsem, C. Punt, P. Hérait, 1999, European journal of cancer.

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.

M. Gore, J. Verweij, G. Creemers, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.

J. Carmichael, D. Armstrong, W. W. ten Bokkel Huinink, 1997, Seminars in oncology.

Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.

R. Stahel, S. Ricci, J. von Pawel, 1999, Lung cancer.

Phase II trial of anaxirone (TGU) in advanced colorectal cancer: an EORTC Early Clinical Trials Group (ECTG) study.

H. Pinedo, G. Decoster, C. Ludwig, 1994, European journal of cancer.

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

H. van Tinteren, H. Tinteren, J. Wagstaff, 1993, British Journal of Cancer.

Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in non-small cell lung cancer.

J. Wanders, J. Mcvie, N. van Zandwijk, 1990, Seminars in oncology.

Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis.

H. Burger, M. Boogaerts, C. Oberhoff, 2006, Anticancer research.

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer.

M. Piccart, M. Gore, J. Wanders, 1995, Journal of the National Cancer Institute.

High sensitivity of radiolabelled antimyosin scintigraphy in assessing anthracycline related early myocyte damage preceding cardiac dysfunction

O. Dalesio, I. Carrió, R. V. Valdés Olmos, 2002, Nuclear medicine communications.

Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction.

H. van Tinteren, P. Bruning, R. V. Valdés Olmos, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

J. Schellens, H. Rosing, J. Beijnen, 2002, Cancer Chemotherapy and Pharmacology.

A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.

S. Ricci, J. von Pawel, P. Kellokumpu-Lehtinen, 1997, Seminars in oncology.

Intraperitoneal chemotherapy: technical experience at five institutions.

D. Alberts, M. Piccart, F. Muggia, 1985, Seminars in oncology.

Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.

W. M. Smit, A. Oza, H. Hirte, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours.

S. Fosså, G. Mead, J. Paul, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.

L. Collette, R. Sylvester, S. Kaye, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ten-year survival and late sequelae in testicular cancer patients treated with cisplatin, vinblastine, and bleomycin.

A. V. van Oosterom, H. Pinedo, G. Stoter, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.

S. Rodenhuis, O. Dalesio, A. V. van Oosterom, 1992, Seminars in oncology.

Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1998, Pharmacy World and Science.

Phase I study and pharmacokinetics of intraperitoneal carboplatin.

J. Mcvie, W. van der Vijgh, W. W. ten Bokkel Huinink, 1985, Cancer treatment reviews.

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group.

R. Sylvester, S. Kaye, P. D. De Mulder, 1995, British Journal of Cancer.

Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.

H. G. van der Poel, M. J. van de Vijver, J. Witjes, 2002, Urology.

Paclitaxel plus carboplatin in the treatment of ovarian cancer.

O. Dalesio, H. Pinedo, B. Winograd, 1995, Seminars in oncology.

Complications of Tenckhoff catheter implantation in patients with multiple previous intraabdominal procedures for ovarian carcinoma.

A. Hart, P. D. de Graaf, W. W. ten Bokkel Huinink, 1988, Gynecologic oncology.

Carboplatin in combination therapy for ovarian cancer.

O. Dalesio, J. Vermorken, N. Rotmensz, 1988, Cancer treatment reviews.

Phase II study of iproplatin in advanced ovarian carcinoma.

F. Cavalli, D. Smith, C. Sessa, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer.

J. Mcvie, B. Taal, G. Simonetti, 1990, Cancer investigation.

Docetaxel: a new active agent in the therapy of metastatic breast cancer.

P. Fumoleau, M. Trudeau, A. Seidman, 1997, Expert opinion on investigational drugs.

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

L. Collette, R. Sylvester, A. V. van Oosterom, 1998, British Journal of Cancer.

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

C. Sternberg, N. Pavlidis, S. Kaye, 1994, British Journal of Cancer.

Feasibility study of high-dose carboplatin and etoposide in the salvage treatment of testicular cancer.

S. Rodenhuis, J. Wanders, D. Richel, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients.

M. J. van de Vijver, W. Meinhardt, S. Horenblas, 2001, The Journal of urology.

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1997, British Journal of Cancer.

I‐123 MIBG and Serial Radionuclide Angiocardiography in Doxorubicin‐related Cardiotoxicity

R. V. Valdés Olmos, W. W. ten Bokkel Huinink, J. Greve, 1992, Clinical nuclear medicine.

Hypersensitivity Reactions to Etoposide

J. Beijnen, J. Schornagel, R. Hoetelmans, 1996, The Annals of pharmacotherapy.

Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.

G. Giaccone, O. Dalesio, P. Postmus, 1994, Seminars in oncology.

Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients.

S. Rodenhuis, W. W. ten Bokkel Huinink, A. Hiemstra, 1997, European journal of cancer.

Phase I trial of N-methylformamide.

J. Mcvie, G. Simonetti, W. W. ten Bokkel Huinink, 1984, Cancer treatment reports.

Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

S. Rodenhuis, J. Verweij, J. Schellens, 1996, Cancer Chemotherapy and Pharmacology.

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group.

A. te Velde, J. Verweij, L. Dirix, 1996, European journal of cancer.

A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group.

M. Piccart, J. Wanders, J. Verweij, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III study.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1987, International journal of andrology.

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

S. Aamdal, H. McLeod, J. Wanders, 1996, British Journal of Cancer.

Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.

A. te Velde, S. Aamdal, R. Paridaens, 1996, British Journal of Cancer.

Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

J. Klijn, J. Verweij, J. Schornagel, 1989, Journal of Urology.

Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.

A. C. Dubbelman, H. Rosing, J. Beijnen, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.

M. Piccart, M. Nooij, M. Franchi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics of 4′-epi-doxorubicin in man

J. Lankelma, J. Mcvie, H. Pinedo, 2004, Investigational New Drugs.

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.

J B Vermorken, K. Swenerton, E. Eisenhauer, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of anaxirone (1,2,4-triglycidylurazol, TGU) in patients with advanced ovarian carcinoma: an EORTC Gynecological Cancer Cooperative Group Study.

J. Vermorken, N. Rotmensz, P. Dodion, 1987, European journal of cancer & clinical oncology.

Primary resistance of renal adenocarcinoma to 1,2,4-triglycidylurazol (TGU, NSC 332488), a new triexpoxide cytostatic agent--a phase II study of the EORTC early clinical trials group.

M. van Glabbeke, H. Hansen, H. Pinedo, 1986, European journal of cancer & clinical oncology.

High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).

H. Bonnefoi, I. Vergote, C. Coens, 2003, European journal of cancer.

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.

A Gordon, M. Gore, J. Carmichael, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group.

E. Eisenhauer, K. Swenerton, W. W. ten Bokkel Huinink, 1993, Cancer treatment reviews.

A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel

J. Schellens, J. Beijnen, L. V. van Warmerdam, 1999, Journal of Cancer Research and Clinical Oncology.

The pharmacokinetics of reduced folates after intraperltoneal and intravenous administration of racemic [6S,R]-folinic acid

S. Rodenhuis, J. Beijnen, O. Tellingen, 2004, Cancer Chemotherapy and Pharmacology.

High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.

M. Forni, J. Vermorken, G. Bolis, 1995, European journal of gynaecological oncology.

D-TRP-6-LHRH (Triptorelin) is not effective in ovarian carcinoma: an EORTC Gynaecological Cancer Co-operative Group Study

M. Piccart, M. Nooij, M. Namer, 2001, Anti-cancer drugs.

Compassionate use programme of irinotecan in colorectal cancer patients in The Netherlands.

H. Keizer, E. Voest, J. D. de Witte, 2003, The Netherlands journal of medicine.

Phase II study of 5-aza-2'-deoxycytidine in advanced ovarian carcinoma. The EORTC Early Clinical Trials Group.

F. Cavalli, C. Sessa, G. Stoter, 1990, European journal of cancer.

Prognostic factors in metastatic non-seminomatous germ cell tumours: an interim analysis of the EORTC GU-Group experience.

R. Sylvester, S. Kaye, G. Stoter, 1993, European urology.

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

J. Schellens, J. Beijnen, G. Groenewegen, 2002, Cancer Chemotherapy and Pharmacology.

Phase I Pharmacokinetic and Pharmacodynamic Study of Carboplatin and Topotecan Administered Intravenously Every 28 Days to Patients with Malignant Solid Tumors

J. Schellens, H. Rosing, J. Beijnen, 2009, Clinical Cancer Research.

An EORTC phase II study of methyl-glyoxal bis-guanylhydrazone in advanced renal cell cancer.

S. Fosså, G. Stoter, J. Child, 1982, European journal of cancer & clinical oncology.

Phase II study of amsacrine in refractory lymphomas. A report of the EORTC Early Clinical Trials Group.

M. van Glabbeke, V. Bramwell, W. W. ten Bokkel Huinink, 1984, European journal of cancer & clinical oncology.

Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol®) and carboplatin in non-small cell lung cancer patients

G. Giaccone, J. Schellens, J. Beijnen, 2000, Anti-cancer drugs.

Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer

M. Muller, W. Meinhardt, L. Moonen, 2008, Acta oncologica.

Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.

S. Aamdal, J. Wanders, C. Sessa, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin in ovarian cancer.

C. Sessa, A. du Bois, W. W. ten Bokkel Huinink, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of vindesine in disseminated squamous cell carcinoma of the uterine cervix: an EORTC Gynecological cancer Cooperative Group study

M. Piccart, F. Landoni, J. Vermorken, 1991, International Journal of Gynecologic Cancer.

Urinary excretion of paclitaxel and metabolites in a large series study

H. Rosing, J. Beijnen, L. V. van Warmerdam, 1998 .

Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours

J. Schellens, H. Rosing, J. Beijnen, 1999, Cancer Chemotherapy and Pharmacology.

Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma.

G. Ross, W. W. ten Bokkel Huinink, S. Lane, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration

J. Schellens, H. Rosing, J. Beijnen, 2000, Anti-cancer drugs.

The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

Phase II study of vincristine, bleomycin, mitomycin C and cisplatin (VBMP) in disseminated squamous cell carcinoma of the uterine cervix.

O. Dalesio, C. Mangioni, J. Vermorken, 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer.

J. Verweij, J. Schornagel, A. de Graeff, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.

F. V. van Leeuwen, J. Gietema, R. de Wit, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitoxantrone and GM-CSF: a phase I study with an escalated dose of mitoxantrone in breast cancer.

S. Rodenhuis, O. Dalesio, H. van Tinteren, 1992, Pathologie-biologie.

Phase I Study of High-Dose Epirubicin in Platinum-Pretreated Patients with Ovarian Carcinoma

M. Piccart, M. Forni, J. Vermorken, 1999, Oncology.

Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.

J. Vermorken, W. van der Vijgh, G. Schwartsmann, 1989, European journal of cancer & clinical oncology.

Phase I study of ethylenediamine platinum(II) malonate (NSC 146 068), a second generation platinum analogue.

J. Mcvie, H. Pinedo, J. Vermorken, 1986, Cancer research.

Experimental and clinical results with intraperitoneal cisplatin.

J. Mcvie, W. W. ten Bokkel Huinink, H. Franklin, 1985, Seminars in oncology.

Experience with independent radiological review during a topotecan trial in ovarian cancer.

M. Gore, S. Gwyther, J. Verweij, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.

S. Rodenhuis, O. Dalesio, J. Beijnen, 1997, Seminars in oncology.

Advanced ovarian cancer. Carboplatin versus cisplatin.

E. Eisenhauer, S. Kaye, P. Conte, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

A pilot study of CHAC-1.

J. Vermorken, W. W. ten Bokkel Huinink, M. V. vd Burg, 1985, Cancer treatment reviews.

Multicenter phase II study of spiroplatin.

H. Pinedo, D. Sleijfer, J. Vermorken, 1992, Oncology.

Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of aqua (1,1-bis(aminomethyl)cyclohexane) sulfatoplatinum (II) (spiroplatin) during a phase I trial.

J. Mcvie, H. Pinedo, J. Vermorken, 1988, European journal of cancer & clinical oncology.

Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 2001, Anti-cancer drugs.

Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.

M. Aapro, M. Namer, I. Vergote, 2003, European journal of cancer.

Phase II evaluation of bisantrene in metastatic breast cancer.

F. Cavalli, M. Rozencweig, W. W. ten Bokkel Huinink, 1985, Cancer treatment reports.

Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)

R. Sylvester, A. V. van Oosterom, S. Kaye, 1991, European journal of cancer.

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

J. Schellens, H. Rosing, J. Beijnen, 2001, Anti-cancer drugs.

CA 125: A valid marker in ovarian carcinoma patients treated with paclitaxel?

P. Kenemans, R. Verstraeten, W. W. ten Bokkel Huinink, 1996, Cancer.

Predictability of the survival of patients with advanced ovarian cancer.

J. Neijt, W. W. ten Bokkel Huinink, J. van Houwelingen, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy and complications in gynecologic cancer

W. W. ten Bokkel Huinink, 1991, Current opinion in oncology.

Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.

J. Schellens, J. Beijnen, W. W. ten Bokkel Huinink, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.

D. Richel, J. Schellens, H. Rosing, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of recombinant human interferon-gamma in metastatic renal cell carcinoma.

S. Kaye, P. D. De Mulder, W. W. ten Bokkel Huinink, 1990, Journal of biological response modifiers.

Extravasation of topotecan, a report of two cases

J. Beijnen, M. Schot, L. V. van Warmerdam, 1997 .

A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A

J. Schellens, H. Rosing, J. Beijnen, 2001, Cancer Chemotherapy and Pharmacology.